CN103204851A - Benzamide derivative containing fused heterocyclic group and therapeutic use thereof - Google Patents

Benzamide derivative containing fused heterocyclic group and therapeutic use thereof Download PDF

Info

Publication number
CN103204851A
CN103204851A CN 201310003861 CN201310003861A CN103204851A CN 103204851 A CN103204851 A CN 103204851A CN 201310003861 CN201310003861 CN 201310003861 CN 201310003861 A CN201310003861 A CN 201310003861A CN 103204851 A CN103204851 A CN 103204851A
Authority
CN
China
Prior art keywords
amino
pyrimidine
benzamide
methyl
aminophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN 201310003861
Other languages
Chinese (zh)
Inventor
李庶心
赵砚瑾
周燕
刘意林
詹文虎
谢宁
钱鹏宇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Radiation Medicine of CAMMS
Original Assignee
Institute of Radiation Medicine of CAMMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Radiation Medicine of CAMMS filed Critical Institute of Radiation Medicine of CAMMS
Priority to CN 201310003861 priority Critical patent/CN103204851A/en
Publication of CN103204851A publication Critical patent/CN103204851A/en
Pending legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention discloses a benzamide derivative containing a fused heterocyclic group. The benzamide derivative is a compound as presented by formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X, n and Ar are specifically defined in the specification. Furthermore, the invention further discloses a drug using the compound or the salt thereof as an active component, and the drug can be used for treating hyperplastic diseases like a cancer.

Description

The benzamide derivatives and the therepic use thereof that contain the fused heterocycle base
Technical field
The present invention relates to a kind of be used for the treatment of with propagation relative disease contain benzamide derivatives of fused heterocycle base and preparation method thereof, the salt of this derivative and the medicine that is activeconstituents with this compound or its salt class.
Background technology
NSC 630176 mainly contains benzamides and hydroxamic acid; existing result of study shows; benzamide compound is than the hydroxamic acid compound couple histon deacetylase (HDAC) (HDAC1 relevant with cell proliferation; 2; 3,8) have higher selectivity and lower side effect.The benzamides medicine that is in clinical study has MS-275, CS055, MGCD0103, wherein MGCD0103 has higher anti-cancer activity, but it is water-soluble lower, the dog bioavailability is 1-90%, big (the Nancy Zhou et al. of the variation coefficient, 2008, J.Med.Chem., 51:4072-4075).Urgent need will be developed has water-soluble height, the new benzamides compounds that pharmacokinetics character is good.
Summary of the invention
The invention provides a kind of benzamide derivatives that contains fused heterocycle, it is NSC 630176, and their main effect is to bring into play its antitumous effect by the activity of inhibition of histone deacetylase (HDAC1,2,3,8).
The purpose of this invention is to provide fused heterocycle benzamide derivatives and its esters or their solvated compounds.
Another object of the present invention provides the preparation method of this derivative.
The 3rd purpose of the present invention provides the pharmaceutical composition of this derivative.
Specifically, the invention provides a kind of benzamide derivatives that contains fused heterocycle, it has formula I structure:
Figure BSA00000835779200011
Or its pharmacy acceptable salt or solvate
Wherein:
Ar is selected from following groups:
R 1, R 2Be hydrogen or halogen atom (fluorine, chlorine, bromine), or C 1-C 4Alkyl, or C 1-C 4Alkoxyl group, or halo C 1-C 4Alkyl;
N=1,2 or 3;
X is hydrogen or halogen atom (fluorine, chlorine, bromine), or C 1-C 4Alkyl or C 1-C 4Alkoxyl group;
Preferably, the invention provides the compound of (II) structure that has formula, or its pharmacy acceptable salt or solvated compounds:
Figure BSA00000835779200022
N wherein, Ar is described suc as formula (I) structure.
More specifically, the invention provides following compound with formula (II) structure, or its pharmacy acceptable salt or solvated compounds
N-(2-aminophenyl)-4-((4-(glyoxal ethyline is [1,2-a] pyridin-3-yl also) pyrimidine-2-amino) methyl) benzamide;
N-(2-aminophenyl)-4-((4-(1H-imidazo [1,2-a] pyridin-3-yl) pyrimidine-2-amino) methyl) benzamide;
N-(2-aminophenyl)-4-((4-(glyoxal ethyline is [1,2-a] pyrimidin-3-yl also) pyrimidine-2-amino) methyl) benzamide;
N-(2-aminophenyl)-4-((4-(imidazo [1,2-a] pyrimidin-3-yl) pyrimidine-2-amino) methyl) benzamide;
N-(2-aminophenyl)-4-((4-(glyoxal ethyline is [1,2-a] pyrazine-3-yl also) pyrimidine-2-amino) methyl) benzamide;
N-(2-aminophenyl)-4-((4-(glyoxal ethyline is [1,2-b] pyridazine-3-yl also) pyrimidine-2-amino) methyl) benzamide;
N-(2-aminophenyl)-4-((4-(imidazo [1,2-a] pyrazine-3-yl) pyrimidine-2-amino) methyl) benzamide;
N-(2-aminophenyl)-4-((4-(imidazo [1,2-b] pyridazine-3-yl) pyrimidine-2-amino) methyl) benzamide;
N-(2-aminophenyl)-4-((4-(6-bromo-glyoxal ethyline is [1,2-a] pyridin-3-yl also) pyrimidine-2-amino) methyl) benzamide;
N-(2-aminophenyl)-4-(2-(4-(imidazo [1,2-a] pyrimidin-3-yl) pyrimidine-2-amino) ethyl) benzamide;
N-(2-aminophenyl)-4-(2-(4-(glyoxal ethyline is [1,2-a] pyridin-3-yl also) pyrimidine-2-amino) ethyl) benzamide;
Preferably, the invention provides the compound of (III) structure that has formula, or its pharmacy acceptable salt or solvated compounds:
Ar wherein, n is described suc as formula (I).
Ground is more specifically arranged, the invention provides following compound with formula (III) structure, or its pharmacy acceptable salt or solvated compounds:
N-(2-amino-5-fluorophenyl) 4-((4-(glyoxal ethyline is [1,2-a] pyridin-3-yl also) pyrimidine-2-amino) methyl) benzamide;
N-(2-amino-4-fluorophenyl)-4-((4-(glyoxal ethyline is [1,2-a] pyridin-3-yl also) pyrimidine-2-amino) methyl) benzamide;
N-(2-amino-4-fluorophenyl)-4-((4-(imidazo [1,2-a] pyridin-3-yl) pyrimidine-2-amino) methyl) benzamide;
N-(2-amino-4-fluorophenyl)-4-((4-(imidazo [1,2-b] pyridazine-3-yl) pyrimidine-2-amino) methyl) benzamide;
N-(2-amino-4-fluorophenyl)-4-((4-(glyoxal ethyline is [1,2-b] pyridazine-3-yl also) pyrimidine-2-amino) methyl) benzamide;
N-(2-amino-4-fluorophenyl)-4-((4-(imidazo [1,2-a] pyrimidin-3-yl) pyrimidine-2-amino) methyl) benzamide;
N-(2-amino-4-fluorophenyl)-4-((4-(glyoxal ethyline is [1,2-a] pyrimidin-3-yl also) pyrimidine-2-amino) methyl) benzamide;
N-(2-amino-4-fluorophenyl)-4-((4-(glyoxal ethyline is [1,2-a] pyrazine-3-yl also) pyrimidine-2-amino) methyl) benzamide;
N-(2-amino-4-fluorophenyl)-4-((4-(imidazo [1,2-a] pyrazine-3-yl) pyrimidine-2-amino) methyl) benzamide;
The compounds of this invention is as containing basic group, then can with sour salify.
Common salt has organic acid salt, inorganic acid salt etc.Usually organic acid salt relatively more commonly used has citrate, fumarate, oxalate, malate, lactic acid salt, camsilate, tosilate, mesylate etc.; Inorganic acid salt has halogen acid salt, vitriol, phosphoric acid salt, nitrate etc.
For example, with low alkyl group sulfonic acid, as methylsulfonic acid, trifluoromethanesulfonic acid etc. can form mesylate, fluoroform sulphonate; With aryl sulfonic acid, can form tosilate, benzene sulfonate as Phenylsulfonic acid or tosic acid etc.; With organic carboxyl acid, as acetic acid, fumaric acid, tartrate, oxalic acid, toxilic acid, oxysuccinic acid, succsinic acid or citric acid etc. can form corresponding salt; With amino acid, can form glutaminate or aspartate as L-glutamic acid or aspartic acid.With mineral acid, as haloid acid (as hydrofluoric acid, Hydrogen bromide, hydroiodic acid HI, spirit of salt), nitric acid, carbonic acid, sulfuric acid or phosphoric acid etc. also can form corresponding salt.
Second purpose of the present invention provided the method for one or more preparation formulas (I) compounds.
Figure BSA00000835779200041
Particularly, for the compound of formula (II), adopt following route synthetic:
Figure BSA00000835779200042
Compound for formula (III) adopts following route synthetic:
The 3rd purpose of the present invention provides the salt that utilizes benzamide derivatives of the present invention or this compound for the medicine of activeconstituents, is used for the treatment of diseases such as proliferative disease such as cancer.
The inventor confirms that by experiment The compounds of this invention has anti-increment restraining effect to human breast carcinoma (MCF-7), but in the medicine of the solid tumor that application for the treatment of human or animal cell proliferative is correlated with or leukemia.
Can also contain one or more pharmaceutically acceptable carriers in said medicine, described carrier comprises the conventional thinner of pharmaceutical field, vehicle, weighting agent, tackiness agent, wetting agent, disintegrating agent, absorption enhancer, tensio-active agent, absorption carrier, lubricant etc., can also add flavouring agent, sweeting agent etc. in case of necessity.Medicine of the present invention can be made tablet, pulvis, and granula, capsule, various ways such as oral liquid and injecting drug use, the medicine of above-mentioned each formulation all can be according to the ordinary method preparation of pharmaceutical field.
The inventor confirms that by experiment The compounds of this invention has anti-increment restraining effect to human breast carcinoma (MCF-7), but in the medicine of the solid tumor that application for the treatment of human or animal cell proliferative is correlated with or leukemia.
Embodiment:
Below by embodiment exploitativeness of the present invention is described, it will be understood by those of skill in the art that the instruction according to prior art, corresponding technical characterictic is made amendment or replaced, still belong to the scope of protection of present invention
Embodiment 1.N-(2-aminophenyl)-4-((4-(2-methyl isophthalic acid H-imidazo [1,2-a] pyridin-3-yl) pyrimidine-2-amino) methyl) benzamide (compound 1)
Figure BSA00000835779200052
Synthesizing of step 1.1-(glyoxal ethyline is [1,2-a] pyridin-3-yl also) ethyl ketone
Figure BSA00000835779200061
With 10g2-aminopyridine, 10.7g sodium bicarbonate, 22g3-chloro-2, the 4-diacetylmethane joins 100ml1, in the 4-dioxane, 80-90 ℃ of reacting by heating 13h, solution by colourless become orange, the vacuum rotary steam solvent, add methylene dichloride and water extraction three times, merge organic layer, drying, filter, concentrating under reduced pressure with ethyl acetate and sherwood oil crystallization, namely gets white solid 13g, productive rate 70.2%, mp:102-105 ℃.
Step 2. (E)-3,3-(dimethylamino)-1-(glyoxal ethyline is [1,2-a] pyridin-3-yl also) acrylketone synthetic
Figure BSA00000835779200062
Step 1 product 13g is joined among the 100ml DMFDMA, and 100 ℃ of reflux 30h are spin-dried for solvent, add the ethyl acetate of 70ml, filter, and filter cake washes twice with ethyl acetate, dry khaki color solid 8.7g, productive rate 50.91%, mp:146-148 ℃ of getting.
Step 3.4-((4-(glyoxal ethyline is [1,2-a] pyridin-3-yl also) pyrimidine-2-amino) methyl) phenylformic acid
With 4.7g step 2 product, 4.0g4-guanidine tolyl acid, 5.7g salt of wormwood join in the 80ml propyl carbinol, 130 ℃ of heating reflux reaction 15h, the thin-layer chromatography demonstration reacts completely the vacuum rotary steam solvent, cooling is dissolved in water, and removes by filter insolubles, the aqueous solution adds ethyl acetate extraction 1 time, and the water intaking layer adds dilute hydrochloric acid and transfers pH to 5-6, separate out Off-white solid, filter, the flushing of filter cake water, dry, namely get faint yellow solid 3.5g.
Step 4.N-(2-aminophenyl)-4-((4-(2-methyl isophthalic acid H-imidazo [1,2-a] pyridin-3-yl) pyrimidine-2-amino) methyl) benzamide
In the dry three-necked bottle of 100ml, N 2Protection adds 2g step 3 product, 1.6gEDCI down; 0.9gHOBt 80ml heavily steams THF, under the condition of ice bath; drip 1.7gTEA, react 1h with this understanding after, add the 0.72g O-Phenylene Diamine in it; room temperature reaction spends the night, and the vacuum rotary steam solvent adds saturated aqueous sodium carbonate in residue; ultrasonic 10min separates out solid, filters; obtain Off-white solid, recrystallization namely gets compound 0.8g.
1HMR(DMSO-d6)(ppm)：δ2.502-2.510(s，3H)，4.635-4.650(d，2H)，4.892(s，1H)，6.572-6.590(t，1H)，6.765-6.783(d，1H)，6.874-6.944(s，1H)，6.948-6.965(t，1H)，7.350(s，1H)7.488-7.508(d，2H)7.577(s，1H)7.693-7.980(d，2H)，8.052-8.082(t，1H)，8.378(s，1H)，8.997(s，1H)，9.639(s，1H)，9.950(s，1H)。
Figure BSA00000835779200071
Embodiment 2.4-((4-(1H-imidazo [1,2-a] pyridin-3-yl) pyrimidine-2-amino) methyl) N-(2-aminophenyl) benzamide (compound 2)
Synthesizing of step 1.1-(imidazo [1,2-a] pyridin-3-yl) ethyl ketone
4g 2-aminopyridine is joined among the 70mlDMFDMA, 100 ℃ of reflux 14h, decompression is spin-dried for solvent, cooling, add the 8g1-monochloroacetone in it, methylene dichloride 70ml, 50 ℃ of heating reflux reaction 24h, decompression is spin-dried for solvent, cross silicagel column, obtain white solid 3g, productive rate 40.5%, mp:94-96 ℃.
Step 2. (E)-3,3-dimethylamino-1-(imidazo [1,2-a] pyridin-3-yl) acrylketone synthetic
Figure BSA00000835779200074
Synthesis step reference example 1
Product fusing point: mp:185-190 ℃.
Step 3.4-((4-(imidazo [1,2-a] pyridin-3-yl) pyrimidine-2 amino) methyl) is benzoic synthetic
Figure BSA00000835779200075
Synthesis step reference example 1
Step 4.4-((4-(1H-imidazo [1,2-a] pyridin-3-yl) pyrimidine-2-amino) methyl) N-(2-aminophenyl) benzamide
Figure BSA00000835779200081
Synthesis step reference example 1
1HMR(DMSO-d6)(ppm)：δ4.657-4.670(d，2H)，4.875(s，2H)，6.563-6.599(t，1H)，6.753-6.773(d，1H)，6.939-6.975(t，1H)，7.129-7.193(m，2H)，7.518(m，3H)，7.735(s，1H)，7.949-7.968(d，2H)，8.081(s，1H)，8.292(s，1H)，8.502(m，1H)，9.378(s，1H)，9.617(s，1H)，10.238(s，1H)。
Embodiment 3.N-(2-aminophenyl)-4-((4-(glyoxal ethyline is [1,2-a] pyrimidin-3-yl also) pyrimidine-2-amino) methyl) benzamide (compound 3)
Step 1.1-(glyoxal ethyline is [1,2-a] pyrimidin-3-yl also) ethyl ketone
With the 9.0g2-aminopyrimidine, 15g 3-chloro-2, the 4-diacetylmethane joins 100ml1, in the 4-dioxane, 85 ℃ of reflux 30h, the vacuum rotary steam solvent adds ethanol and acetic acid ethyl dissolution impurity, filters, and obtains brick-red crude product 3.4g, mp:85-90 ℃.
Step 2. (E)-3,3-(dimethylamino)-1-(glyoxal ethyline is [1,2-a] pyrimidin-3-yl also) acrylketone
Synthesis step reference example 1
Step 3.4-((4-(glyoxal ethyline is [1,2-a] pyrimidin-3-yl also) pyrimidine-2-amino) methyl) phenylformic acid
Synthesis step reference example 1
Step 4.N-(2-aminophenyl)-4-((4-(glyoxal ethyline is [1,2-a] pyrimidin-3-yl also) pyrimidine-2-amino) methyl) benzamide
Figure BSA00000835779200082
Synthesis step reference example 1
1HMR(DMSO-d6)(ppm)：δ2.499-2.208(s，3H)，4.659(d，2H)，4.879(s，2H)，6.564-6.601(t，1H)，6.754-6.774(d，1H)，6.938-6.976(t，1H)，7.102-7.151(m，2H)，7.354-7.366(d，1H)，7.462-7.502(s，2H)，7.917-7.969(d，3H)，8.394(d，1H)，8.568-8.575(d，1H)，8.787-8.802(d，1H)，9.603-9.625(d，1H)。
Embodiment 4.N-(2-aminophenyl)-4-((4-(imidazo [1,2-a] pyrimidin-3-yl) pyrimidine-2-amino) methyl) benzamide (compound 4)
Step 1.1-(imidazo [1,2-a] pyrimidin-3-yl) ethyl ketone
The 10g2-aminopyrimidine is joined among the 80mlDMFDMA, 100 ℃ of reflux 15h, decompression is spin-dried for solvent, cooling adds 1-monochloroacetone 20g, methylene dichloride 100ml, 50 ℃ of about 30h of reflux, solution becomes brown solution by orange, and decompression is spin-dried for solvent, adding ethanol 80ml stirs, filter, the filter cake ethyl acetate rinse obtains white solid 12.3g, productive rate 72.3%, mp:200-203 ℃.
Step 2. (E)-3,3-(dimethylamino)-1-(imidazo [1,2-a] pyrimidin-3-yl) acrylketone
Synthesis step reference example 1
Step 3.4-((4-(imidazo [1,2-a] pyrimidin-3-yl) pyrimidine-2-amino) methyl) phenylformic acid
Synthesis step reference example 1
Step 4.N-(2-aminophenyl)-4-((4-(imidazo [1,2-a] pyrimidin-3-yl) pyrimidine-2-amino) methyl) benzamide
Figure BSA00000835779200091
Synthesis step reference example 1
1HMR(DMSO-d6)(ppm)：δ4.647-4.662(d，2H)，4.886(s，2H)，6.564-6.600(t，1H)，6.753-6.773(d，1H)，6.940-6.957(t，1H)，7.107-7.153(m，2H)，7.292-7.305(d，1H)，7.524(s，2H)，7.905-7.942(d，3H)，8.401-8.414(m，2H)，8.600-8.614(d，1H)，9.042-9.056(d，1H)，9.610(s，1H)。
Embodiment 5.N-(2-aminophenyl)-4-((4-(glyoxal ethyline is [1,2-a] pyrazine-3-yl also) pyrimidine-2-amino) methyl) benzamide (compound 5)
Synthesis step reference example 1
1HMR(DMSO-d6)(ppm)：δ2.505-2.699(m，3H)，4.643-4.651(d，2H)，4.894(s，2H)，6.571-6.607(t，1H)，6.763-6.781(d，1H)，6.947-6.981(t，1H)，7.138-7.158(d，1H)，7.492-7.512(d，2H)，7.440(s，1H)，7.984(s，2H)，8.193-8.224(t，2H)，8.466(s，1H)，8.710(s，1H)，9.051-9.077(m，1H)，9.669(s，1H)。
Embodiment 6.N-(2-aminophenyl)-4-((4-(imidazo [1,2-a] pyrazine-3-yl) pyrimidine-2-amino) methyl) benzamide (compound 6)
Step 1.1-(imidazo [1,2-a] pyrazine-3-yl) ethyl ketone
The amino pyrazine of 10g2-is joined among the 70mlDMFDMA, 100 ℃ of reflux 18h, the vacuum rotary steam solvent, cooling adds the 25g1-monochloroacetone, heavily steam methylene dichloride 100ml, 50 ℃ of reflux 30h, the vacuum rotary steam solvent is crossed silicagel column (developping agent: ethyl acetate: sherwood oil=4: 1), get faint yellow solid 2.0g with alcohol crystal, productive rate 11.8%.Fusing point: 165-170 ℃.
Step 2 (E)-3,3-(dimethylamino)-1-(imidazo [1,2-a] pyrazine-3-yl) acrylketone
Synthesis step reference example 1
Product fusing point: 193-196 ℃.
Step 3.4-((4-(imidazo [1,2-a] pyrazine-3-yl) pyrimidine-2-amino) methyl) phenylformic acid
Synthesis step reference example 1
Step 4.N-(2-aminophenyl)-4-((4-(imidazo [1,2-a] pyrazine-3-yl) pyrimidine-2-amino) methyl) benzamide
Figure BSA00000835779200101
Synthesis step reference example 1
1HMR(DMSO-d6)(ppm)：δ4.6678-4.6825(d，2H)，4.8702(s，2H)，6.5629-6.6000(t，1H)，6.7562-6.7758(d，1H)，6.9405-6.9762(t，1H)，7.1289-7.1457(s，1H)，7.2732-7.2859(d，1H)，7.5255(s，2H)，7.9661(s，3H)，8.2064(s，1H)，8.3942(s，1H)，8.6618-8.7431(d，1H)，9.1907-9.2342(m，1H)，9.6258(s，1H)，10.1120(s，1H)。
Embodiment 7.N-(2-aminophenyl)-4-((4-(glyoxal ethyline is [1,2-b] pyridazine-3-yl also) pyrimidine-2-amino) methyl)
Benzamide (compound 7)
Synthesizing of step 1.3-amino pyridazine
With 40g3 amino-6-chlorine pyridazine, 4g palladium carbon, 37.4g triethylamine, 3000ml methyl alcohol join in the autoclave of 5L, react 6h under 1.5atm, 60 ℃ of conditions, filter, and filtrate decompression concentrates, and gets white powder 16.7g with ethyl alcohol recrystallization.
Product fusing point: 167-169 ℃.
Step 2.1-(glyoxal ethyline is [1,2-b] pyridazine-3-yl also) ethyl ketone
Under nitrogen protection, with the 10g3-amino pyridazine, 18.4g3-chloro-2,4-diacetylmethane join in the 80ml ethanol, 80 ℃ of reflux 10h, and the vacuum rotary steam solvent is crossed silicagel column (developping agent: ethyl acetate: sherwood oil=1: 2), obtain brown solid 1.4g.
Product fusing point: 130-133 ℃.
Step 3. (E)-3,3-(dimethylamino)-1-(glyoxal ethyline is [1,2-b] pyridazine-3-yl also) acrylketone
Synthesis step reference example 1
Product fusing point: 128-131 ℃.
Step 4.4-((4-(glyoxal ethyline is [1,2-b] pyridazine-3-yl also) pyrimidine-2-amino) methyl) phenylformic acid
Synthesis step reference example 1
Synthesizing of step 5.N-(2-aminophenyl)-4-((4-(glyoxal ethyline is [1,2-b] pyridazine-3-yl also) pyrimidine-2-amino) methyl) benzamide
Figure BSA00000835779200111
Synthesis step reference example 1
1HMR(DMSO-d6)(ppm)：δ2.500-2.652(s，3H)，4.665-4.679(d，2H)，4.866(s，2H)，6.567-6.605(t，1H)，6.761-6.781(d，1H)，6.937-6.928(t，1H)，7.144-7.163(d，1H)，7.330-7.365(t，1H)，7.456-7.476(d，2H)，7.762-7.935(m，4H)，8.128-8.155(dd，1H)，8.428-8.441(d，1H)，8.645-8.656(dd，1H)，9.584(s，1H)。
Embodiment 8.N-(2-aminophenyl)-4-((4-(imidazo [1,2-b] pyridazine-3-yl) pyrimidine-2-amino) methyl) benzamide (compound 8)
Step 1.1-(imidazo [1,2-b] pyridazine-3-yl) acetone
10g 3-amino pyridazine is joined among the 80mlDMFDMA, reflux 18h, the vacuum rotary steam solvent, cooling adds the 20g1-monochloroacetone in it, heavily steams methylene dichloride 100ml, 50 ℃ of reaction 30h, the vacuum rotary steam solvent is crossed silicagel column (developping agent: ethyl acetate: be raw material sherwood oil=2: 1), obtain safran solid 0.8g.
Product fusing point: 126-133 ℃.
Step 2. (E)-3,3-(dimethylamino)-1-imidazo [1,2-b] pyridazine-3-yl) acrylketone
Synthesis step reference example 1
Step 3 4-((4-(imidazo [1,2-b] pyridazine-3-yl) pyrimidine-2-amino) methyl) phenylformic acid
Synthesis step reference example 1
Step 4.N-(2-aminophenyl)-4-((4-(imidazo [1,2-b] pyridazine-3-yl) pyrimidine-2-amino) methyl) benzamide
Figure BSA00000835779200121
Synthesis step reference example 1
MS(FAB)：437(M+1)
Embodiment 9.N-(2-aminophenyl)-4-((4-(6-bromo-2-methyl isophthalic acid H-imidazo [1,2-a] pyridin-3-yl) pyrimidine-2-amino) methyl) benzamide (compound 9)
Figure BSA00000835779200122
Synthesis step reference example 1
1HMR(DMSO-d6)(ppm)：δ2.500-2.509(m，3H)，4.664-4.678(d，2H)，4.877(s，1H)，6.564-6.600(t，3H)，6.754-6.773(d，1H)，6.898-6.976(m，2H)，7.124-7.139(s，1H)，7.918-7.938(d，2H)，8.123-8.224(m，1H)，8.398(s，1H)，9.610(s，1H)，9.817-9.995(d，1H)。
Embodiment 10.N-(2-amino-4-fluorophenyl)-4-((4-(2-methyl isophthalic acid H-imidazoles [1,2-a] pyridin-3-yl) pyrimidine-2-amino) methyl) benzamide (compound 10)
Reference example 1 synthetic 4-((4-(glyoxal ethyline is [1,2-a] pyridin-3-yl also) pyrimidine-2-amino) methyl) phenylformic acid; With 1.5g4-((4-(glyoxal ethyline is [1,2-a] pyridin-3-yl also) pyrimidine-2-amino) methyl) phenylformic acid, 1.0gN, N-phosphinylidyne diimidazole is dissolved in the 70ml anhydrous tetrahydro furan, 60 ℃ of reaction 24h, cooling, standby.Get another dry 100ml three-necked bottle, under nitrogen protection, with 0.58g4-fluoro-1; the 2-phenylenediamine is dissolved in the 20ml anhydrous tetrahydro furan, under the condition of ice bath, drips the 0.52g trifluoroacetic acid; drip standby reaction solution again, 40 ℃ of stirrings are spent the night, and TCL shows that reaction finishes; decompression and solvent recovery, residue are poured in the unsaturated carbonate aqueous solutions of potassium, ethyl acetate and three times (80ml*3) of water extraction; merge organic layer; drying concentrates and obtains oily matter, gets compound 0.56g with ethyl alcohol recrystallization.
Figure BSA00000835779200123
1HMR(DMSO-d6)(ppm)：δ2.500-2.590(s，3H)，4.625-4.640(d，2H)，5.209(s，2H)，6.341-6.348(t，1H)，6.507-6.542(dd，1H)，6.865-6.876(d，1H)，7.073-7.111(t，1H)，7.457-7.581(m，4H)，7.946-8.056(m，3H)，8.379(s，1H)，9.005(s，1H)，9.553(s，1H)，9.959(s，1H)。
Embodiment 11.N-(2-amino-5-fluorophenyl) 4-((4-(2-methyl isophthalic acid H-imidazo [1,2-a] pyridin-3-yl) pyrimidine-2-amino) methyl) benzamide (compound 11)
Reference example 1 synthetic 4-((4-(glyoxal ethyline is [1,2-a] pyridin-3-yl also) pyrimidine-2-amino) methyl) phenylformic acid; In the 100ml of drying three-necked bottle; under the nitrogen protection, add 1.4g4-((4-(glyoxal ethyline is [1,2-a] pyridin-3-yl also) pyrimidine-2-amino) methyl) phenylformic acid; EDCI1.1g; HOBt0.63g, anhydrous THF40ml, DMF10ml; drip triethylamine 0.78g under the condition of ice bath; behind the room temperature reaction 2h, add 1.0gN-Boc-2-amino-4-fluoroaniline then, room temperature reaction spends the night; the vacuum rotary steam solvent; residue adds ethyl acetate and three times (80ml*3) of water extraction, merges organic layer, concentrates; cross silicagel column; eluent ethyl acetate/petroleum ether=2: 1 and methylene chloride=20: 1, elutriant concentrates, and obtains solid chemical compound 0.7g with alcohol crystal.
0.7g is gone up the step product to be suspended in the 50ml methylene dichloride, add the 20ml concentrated hydrochloric acid, room temperature reaction 3h, TLC show that reaction finishes the vacuum rotary steam solvent, residue adds sodium carbonate solution and transfers pH to 8, separate out white solid, filter, filter cake washes with water twice, use then ethyl acetate and sherwood oil (2: 1) mixed solution wash-out 2 times, alcohol crystal gets solid 0.5g.
Figure BSA00000835779200131
MS(FAB)：468(M+1)
Embodiment 12.4-((4-(1-H-imidazo [1,2-a] pyridin-3-yl) pyrimidine-2 amino) methyl) N-(2-amino-4-fluorophenyl) benzamide (compound 14)
Figure BSA00000835779200132
Synthesis step reference example 2 and embodiment 10
MS(FAB)：454(M+1)
Embodiment 13.N-(2-amino-4-fluorophenyl)-4-((4-(imidazo [1,2-b] pyridazine-3-yl) pyrimidine-2-amino) methyl) benzamide (compound 12)
Figure BSA00000835779200141
Synthesis step reference example 8 and embodiment 10
MS(FAB)：455(M+1)
Embodiment 14.N-(2-amino-4-fluorophenyl)-4-((4-(glyoxal ethyline is [1,2-b] pyridazine-3-yl also) pyrimidine-2-amino) methyl) benzamide (compound 13)
Figure BSA00000835779200142
Synthesis step reference example 7 and embodiment 10
MS(FAB)：469(M+1)
Embodiment 15.N-(2-amino-4-fluorophenyl)-4-((4-(imidazo [1,2-a] pyrimidin-3-yl) pyrimidine-2-amino) methyl) benzamide (compound 15)
Figure BSA00000835779200143
Synthesis step reference example 4 and embodiment 10
MS(FAB)：455(M+1)
Embodiment 16.N-(2-amino-4-fluorophenyl)-4-((4-(glyoxal ethyline is [1,2-a] pyrimidin-3-yl also) pyrimidine-2-amino) methyl) benzamide (compound 16)
Figure BSA00000835779200144
Synthesis step reference example 3 and embodiment 10
MS(FAB)：469(M+1)
Embodiment 17.N-(2-amino-4-fluorophenyl)-4-((4-(glyoxal ethyline is [1,2-a] pyrazine-3-yl also) pyrimidine-2-amino) methyl) benzamide (compound 17)
Figure BSA00000835779200151
Synthesis step reference example 5 and embodiment 10
MS(FAB)：469(M+1)
Embodiment 18.N-(2-amino-4-fluorophenyl)-4-((4-(imidazo [1,2-a] pyrazine-3-yl) pyrimidine-2-amino) methyl) benzamide (compound 18)
Figure BSA00000835779200152
Synthesis step reference example 6 and embodiment 10
MS(FAB)：455(M+1)
Embodiment 19.N-(2-aminophenyl)-4-(2-(4-(imidazo [1,2-a] pyrimidin-3-yl) pyrimidine-2-amino) ethyl) benzamide (compound 19)
Step 1 4-((4-(imidazo [1,2-a] pyrimidin-3-yl) pyrimidine-2-amino) ethyl) phenylformic acid
Reference example 4 synthetic (E)-3,3-(dimethylamino)-1-(imidazo [1,2-a] pyrimidin-3-yl) acrylketone; With 4.3g (E)-3,3-(dimethylamino)-1-(imidazo [1,2-a] pyrimidin-3-yl) acrylketone, 5.9g guanidine ethylamino benzonitrile tert-butyl acrylate and 5.5 salt of wormwood join in the 100ml propyl carbinol, 130 ℃ of reflux 15h, cooling is filtered, and filtrate decompression is spin-dried for, add dilute hydrochloric acid and transfer pH to 4-5, with ethyl acetate extraction 3 times, merge organic layer, use anhydrous Na SO 4Drying is filtered, and is spin-dried for, and obtains oily matter, adds the 50ml concentrated hydrochloric acid in it, 100ml water, and heating reflux reaction 3h, vacuum rotary steam part water is transferred pH to 3-4 with the NaOH aqueous solution, uses K again 2CO 3Transfer pH to 6-7, separate out solid, filter, obtain the about 3.1g of compound.
Step 4.N-(2-aminophenyl)-4-(2-(4-(imidazo [1,2-a] pyrimidin-3-yl) pyrimidine-2-amino) ethyl) benzamide
Synthesis step reference example 1
Figure BSA00000835779200161
1HMR(DMSO-d6)(ppm)：δ3.001(s，2H)，3.617-3.631(d，2H)，4.896(s，2H)，6.579-6.615(t，1H)，6.768-6.788(d，1H)，6.952-6.987(t，1H)，7.110-7.167(m，2H)，7.280-7.292(d，2H)，7.423-7.440(d，2H)，7.793-7.950(d，2H)，8.417(m，2H)，8.603-8.613(t，1H)，9.044-9.061(dd，1H)，9.628(s，1H)。
Embodiment 20.N-(2-aminophenyl)-4-(2-(4-(glyoxal ethyline is [1,2-a] pyridin-3-yl also) pyrimidine-2-amino) ethyl) benzamide (compound 20)
Synthesis step reference example 1, embodiment 10 and embodiment 19
Figure BSA00000835779200162
1HMR(DMSO-d6)(ppm)：δ3.014(s，2H)，3.653(s，2H)，4.911(s，2H)，6.585-6.622(t，1H)，6.778-6.798(dd，1H)，6.955-6.997(t，1H)，7.127-7.185(m，3H)，7.422-7.574(m，4H)，7.759-7.781(d，1H)，7.905-7.965(d，2H)，8.299(s，1H)，8.556(s，1H)，9.647(s，1H)，10.020-10.176(d，1H)。
Embodiment 21: compound in-vitro multiplication restraining effect
Mtt assay is measured compound to the growth-inhibiting effect of MCF-7 (MCF-7).Compound is dissolved cryopreservation with DMSO.To be grown in the cell of logarithmic phase, the trysinization through 0.01%, counting is with 2.0 * 10 3The cell density of/well is seeded in 100ml in 96 orifice plates, places 5%CO 237 ℃ of overnight incubation in the incubator.Each compound is established six concentration gradients, and each concentration is established three multiple holes, and each concentration joins respectively in the corresponding aperture, 5%CO 2Cultivated 72 hours in 37 ℃ of incubators, add the 5mg/mlMTT of 20ml.37 ℃ hatch 3 hours after, inhale and to abandon supernatant, add the DMSO dissolving of 100ml, use SpectraMAX340 to survey 550nm (L1) absorbance value, reference wavelength 690nm (L2) maps (L1-L2) value to the inhibitor different concns, get IC through formula fitting 50
Table 1 compound is to MCF-7 MCF-7 inhibited proliferation
Compound IC 50 Error
MGCD0103 4.807 0.181
Compound 1 2.088 0.626
Compound 2 0.661 0.156
Compound 3 4.111 1.186
Compound 4 0.856 0.271
Compound 5 3.741 1.265
Compound 6 2.178 0.801
Compound 7 7.155 1.821
Compound 8 8.347 1.521
Compound 9 2.359 0.148
Compound 10 2.400 0.934
Compound 11 1.004 0.265
Compound 12 5.467 1.747
Compound 13 1.478 1.168
Compound 14 2.896 0.784
Compound 15 3.763 0.832
Compound 16 7.498 1.636
Compound 17 8.129 1.763
Compound 18 3.468 1.076
Compound 19 1.723 0.893
Compound 20 4.119 0.579
Conclusion: the inhibition activity of compound 2,3 pairs of tumours is about 6 times of positive control MGCD0103, and the inhibition activity of compound 1,4,5,6,10 pairs of tumours is compared the raising that significance is also arranged with positive control MGCD0103.
Embodiment 22: the test of rat pharmacokinetics
Precision takes by weighing a certain amount of compound, with dissolution with solvents or make suspension, give the SD rat oral gavage or and tail vein injection, irritating the stomach amount is every about 0.5ml of animal, the about 0.3ml of every animal of intravenous injection.Different time points blood sampling after the administration, anticoagulant heparin, the centrifugal 10min of 8000rpm, separated plasma, interior mensuration with the good HPLC-MS quantivative approach of foundation finishes on the same day.
The about 0.5ml of amount for taking blood separates obtaining the about 0.2ml of blood plasma.
Before the getting the blood time point and be administration of gastric infusion, 5min after the administration, 15min, 30min, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h.Before the getting the blood time point and be administration of intravenously administrable, 1min after the administration, 5min, 15min, 30min, 1h, 2h, 4h, 6h, 8h, 12h, 24h.
Compound solvent and the dosage of each experiment are different.
6 rats are divided into 2 groups at random, and 3 every group, vein and filling stomach give compound (1) respectively, and intravenously administrable dosage 5mg/kg uses N, the dinethylformamide dissolving; Gastric infusion dosage 50mg/kg is made into suspension with (containing 0.5%CMC-Na, 1% tween-80,0.1mol/L HCl) physiological saline.
Pharmacokinetic parameter (50mg/kg) in the blood plasma of the oral single-dose compound of table 2 (1) back
Figure BSA00000835779200181
Pharmacokinetic parameter in table 3 (MGCD0103) document
Figure BSA00000835779200182
Document (Nancy Zhou et al., 2008, J.Med.Chem., 51:4072-4075) bioavailability of report N-(2-aminophenyl)-4-((4-pyridin-3-yl-pyrimidine-2-amino) methyl) benzamide (MGCD0103) rat is 47%, the bioavailability of comparing our compound with it is 81%, and the bioavailability of the former dog is 1-92, and the variation coefficient is bigger.Therefore, our designed target compound has pharmacokinetic property preferably.

Claims (8)

1. general formula (I) structural compounds, or its pharmacy acceptable salt or solvated compounds:
Figure FSA00000835779100011
Wherein:
X is hydrogen or halogen atom (fluorine, chlorine, bromine), or C 1-C 4Alkyl or C 1-C 4Alkoxyl group;
N=1,2 or 3;
Ar is selected from following groups:
Figure FSA00000835779100012
R 1, R 2Be hydrogen or halogen atom (fluorine, chlorine, bromine), or C 1-C 4Alkyl, or C 1-C 4Alkoxyl group, or halo C 1-C 4Alkyl.
2. in the compound according to claim 1, wherein, X is hydrogen.
3. according to the described compound of arbitrary right among the claim 1-2, it is characterized in that described compound has following formula structure (II):
Figure FSA00000835779100013
Or its pharmacy acceptable salt or solvated compounds
N wherein, Ar such as according to arbitrary requirement among the claim 1-2 definition.
4. compound according to claim 3 is characterized in that described compound is:
N-(2-aminophenyl)-4-((4-(glyoxal ethyline is [1,2-a] pyridin-3-yl also) pyrimidine-2-amino) methyl) benzamide;
N-(2-aminophenyl)-4-((4-(1H-imidazo [1,2-a] pyridin-3-yl) pyrimidine-2-amino) methyl) benzamide;
N-(2-aminophenyl)-4-((4-(glyoxal ethyline is [1,2-a] pyrimidin-3-yl also) pyrimidine-2-amino) methyl) benzamide;
N-(2-aminophenyl)-4-((4-(imidazo [1,2-a] pyrimidin-3-yl) pyrimidine-2-amino) methyl) benzamide;
N-(2-aminophenyl)-4-((4-(glyoxal ethyline is [1,2-a] pyrazine-3-yl also) pyrimidine-2-amino) methyl) benzamide;
N-(2-aminophenyl)-4-((4-(glyoxal ethyline is [1,2-b] pyridazine-3-yl also) pyrimidine-2-amino) methyl) benzamide;
N-(2-aminophenyl)-4-((4-(imidazo [1,2-a] pyrazine-3-yl) pyrimidine-2-amino) methyl) benzamide;
N-(2-aminophenyl)-4-((4-(imidazo [1,2-b] pyridazine-3-yl) pyrimidine-2-amino) methyl) benzamide;
N-(2-aminophenyl)-4-((4-(6-bromo-glyoxal ethyline is [1,2-a] pyridin-3-yl also) pyrimidine-2-amino) methyl) benzamide;
N-(2-aminophenyl)-4-(2-(4-(imidazo [1,2-a] pyrimidin-3-yl) pyrimidine-2-amino) ethyl) benzamide;
N-(2-aminophenyl)-4-(2-(4-(glyoxal ethyline is [1,2-a] pyridin-3-yl also) pyrimidine-2-amino) ethyl) benzamide.
5. compound according to claim 1 is characterized in that described compound has following structural (III):
Figure FSA00000835779100021
Or its pharmacy acceptable salt or solvated compounds
Ar wherein, n as defined in claim 1, X is fluorine.
6. compound according to claim 5 is characterized in that described compound is:
N-(2-amino-5-fluorophenyl) 4-((4-(glyoxal ethyline is [1,2-a] pyridin-3-yl also) pyrimidine-2-amino) methyl) benzamide;
N-(2-amino-4-fluorophenyl)-4-((4-(glyoxal ethyline is [1,2-a] pyridin-3-yl also) pyrimidine-2-amino) methyl) benzamide;
N-(2-amino-4-fluorophenyl)-4-((4-(imidazo [1,2-a] pyridin-3-yl) pyrimidine-2-amino) methyl) benzamide;
N-(2-amino-4-fluorophenyl)-4-((4-(imidazo [1,2-b] pyridazine-3-yl) pyrimidine-2-amino) methyl) benzamide;
N-(2-amino-4-fluorophenyl)-4-((4-(glyoxal ethyline is [1,2-b] pyridazine-3-yl also) pyrimidine-2-amino) methyl) benzamide;
N-(2-amino-4-fluorophenyl)-4-((4-(imidazo [1,2-a] pyrimidin-3-yl) pyrimidine-2-amino) methyl) benzamide;
N-(2-amino-4-fluorophenyl)-4-((4-(glyoxal ethyline is [1,2-a] pyrimidin-3-yl also) pyrimidine-2-amino) methyl) benzamide;
N-(2-amino-4-fluorophenyl)-4-((4-(glyoxal ethyline is [1,2-a] pyrazine-3-yl also) pyrimidine-2-amino) methyl) benzamide;
N-(2-amino-4-fluorophenyl)-4-((4-(imidazo [1,2-a] pyrazine-3-yl) pyrimidine-2-amino) methyl) benzamide.
7. a pharmaceutical composition contains the described compound of arbitrary claim or its pharmacy acceptable salt and pharmaceutically acceptable carrier among one or more claims 1-6.
8. the described compound of arbitrary claim or its pharmacy acceptable salt application in the medicine for preparing the relevant solid tumor for the treatment of human or animal cell proliferative or leukemia in the claim 1-6 item.
CN 201310003861 2012-01-12 2013-01-06 Benzamide derivative containing fused heterocyclic group and therapeutic use thereof Pending CN103204851A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 201310003861 CN103204851A (en) 2012-01-12 2013-01-06 Benzamide derivative containing fused heterocyclic group and therapeutic use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201210007851 2012-01-12
CN201210007851.X 2012-01-12
CN 201310003861 CN103204851A (en) 2012-01-12 2013-01-06 Benzamide derivative containing fused heterocyclic group and therapeutic use thereof

Publications (1)

Publication Number Publication Date
CN103204851A true CN103204851A (en) 2013-07-17

Family

ID=48752281

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 201310003861 Pending CN103204851A (en) 2012-01-12 2013-01-06 Benzamide derivative containing fused heterocyclic group and therapeutic use thereof

Country Status (1)

Country Link
CN (1) CN103204851A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015006875A1 (en) * 2013-07-18 2015-01-22 Methylgene Inc. Process for the preparation of substituted pyrimidines

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015006875A1 (en) * 2013-07-18 2015-01-22 Methylgene Inc. Process for the preparation of substituted pyrimidines

Similar Documents

Publication Publication Date Title
CN102186842B (en) Hydroxamic acid derivatives
JP5719770B2 (en) Icotinib hydrochloride, compound, crystallographic form, concomitant drug and its use
CN101759683B (en) Preparation method of hydrindene amide compound, medical composition comprising hydrindene amide compound and application thereof as protein kinase inhibitor
ES2773543T3 (en) Benzoimidazol-2-ylpyrimidines histamine H4 receptor modulators
BR112017003312B1 (en) INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITORS, PREPARATION AND USE THEREOF
JP2017526727A (en) Indoleamine-2,3-dioxygenase inhibitor and method for producing the same
CN102295635B (en) Antitumor medicament tetralin amide compounds and pharmaceutically acceptable salts thereof as well as preparation method and application of antitumor medicament tetralin amide compounds
ES2772498T3 (en) Preparation of a mek inhibitor and formulation comprising the same
CN101155786A (en) N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
CN102391191B (en) Piperazine di-thiocarboxylic acid ester derivative of 2,4-di-aminoquinazoline, as well as preparation method and anti-tumor application of the derivative
CN106478605A (en) Pyrimidines, its preparation method and medical usage
CN104003925B (en) Oxindole compounds or derivatives thereof and uses thereof
JP6913955B2 (en) Molten quinoline compound as PI3K / mTOR inhibitor
CN104250253A (en) Substituted tetrahydronaphthalene amide compound, pharmaceutically acceptable salt thereof, and preparation method and application
ES2914526T3 (en) Biaryl Compositions and Methods for Modulating a Kinase Cascade
CN104334530A (en) Solid state forms of n-((s)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide
CN103204851A (en) Benzamide derivative containing fused heterocyclic group and therapeutic use thereof
CN106831707A (en) As the benzheterocycle analog derivative and its medical application of c Met kinase inhibitors
JPS62252780A (en) Novel indenothiazole derivative and production thereof
WO2019001307A1 (en) Amide compound, composition containing same, and use thereof
KR101546743B1 (en) Indole derivatives, Abl kinase inhibiting composition and pharmaceutical compositions for prevention and treatment of abnormal cell growth diseases comprising the same
EP4063361A1 (en) Crystal forms of fused ring compound, and composition thereof, preparation method therefor and application thereof
KR20230167009A (en) A potent and selective inhibitor of HER2
CN112888690B (en) Salts of substituted pyrrolopyrimidine CDK inhibitors, crystals thereof and use thereof
CN107698484A (en) A kind of preparation method of derivative of lenalidomide and application

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C05 Deemed withdrawal (patent law before 1993)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130717